ABBV - AbbVie Inc.
After hours:
| Previous close | 136.50 |
| Open | 137.00 |
| Bid | 137.58 x 1000 |
| Ask | 137.57 x 800 |
| Day's range | 136.00 - 137.88 |
| 52-week range | 131.10 - 168.11 |
| Volume | |
| Avg. volume | 5,978,704 |
| Market cap | 242.837B |
| Beta (5Y monthly) | 0.55 |
| PE ratio (TTM) | 32.39 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.92 (4.37%) |
| Ex-dividend date | 13 Apr 2023 |
| 1y target est | N/A |
- GlobeNewswire
Sirona Biochem Announces the Termination of Supply Agreement with Rodan + Fields
VANCOUVER, British Columbia, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) announces the termination of the Rodan + Fields (R+F) agreement for supply and use of TFC-1067 in commercial formulations. Allergan Aesthetics, an AbbVie company (NYSE: ABBV), will now be the sole licensee of the technology as per the agreement signed June 2022. About Sirona Biochem Corp.Sirona Biochem is a cosmetic ingredient and drug discovery company with a propr
- Business Wire
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
NORTH CHICAGO, Ill. & EXTON, Pa., January 06, 2023--AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine.
- Business Wire
CIBC Launches 5 New CDRs ("Canadian Depositary Receipts") on the NEO Exchange
TORONTO, November 25, 2022--NEO is proud to welcome CIBC back to the NEO Exchange with a suite of five new CDRs™ to expand their existing lineup to 35 global companies.
- GlobeNewswire
Sosei Heptares and AbbVie Enter New Multi-target Collaboration to Discover, Develop and Commercialize Novel Medicines Targeting Neurological Diseases
New strategic collaboration leverages Sosei Heptares’ StaR® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration with AbbVie follows 2020 agreement focused on inflammatory and autoimmune diseasesSosei Heptares eligible to receive up to $80 million in upfront and near-term milestone payments and has potential to receive further downstream payments totalling up to US$1.2 billion, plus tiered royalties TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 02, 2
- Business Wire
Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
COPENHAGEN, Denmark, July 18, 2022--Genmab A/S (Nasdaq: GMAB) today announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) with the European Medicines Agency (EMA) for subcutaneous epcoritamab (DuoBody®-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), in the second half of 2022. Genmab recently announced that the company will submit a biologics license a
- GlobeNewswire
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics
Licenses Revolutionary Skin Care Compound TFC-1067VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona”) is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin care treatments based on active ingredients derived from certain of Sirona’s patents for TFC-106
